Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063205144> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2063205144 abstract "Antiviral therapy post-transplantation has a limited efficacy. There is an interest in determining whether the use of growth factors, particularly erythropoietin (EPO) may improve the results. Aim: To assess whether the use of EPO has an effect in the efficacy (sustained virologic response-SVR-) and tolerability (premature discontinuation & dose reductions of ribavirin-RBVR) of antiviral therapy with pegIFN-RBVR ribavirin. Methods: 138 LT patients (74% men, mean age:55.5 years, 85% genotype 1a-b)with recurrent hepatitis C were treated with pegIFN-ribavirin (pegasys 58%) between 2001 and 2009. Baseline and outcome measures were compared between those receiving EPO and those without. Results: An SVR was achieved in 58 patients (42%). Variables independently associated with SVR were baseline disease severity, genotype, donor age and adherence (RBVR and IFN premature discontinuation). In addition, viral kinetics were highly predictive of treatment outcome. Epo was used in 80 patients (58%) with a greater use in recent years (71% of those treated between 2005– 2009 vs 35% in those treated during 2001–2004; p 1.5mg/dl used EPO vs 50% of those with levels <1.5mg/dl, p < 0.001), mycophenolate use at baseline (86% vs 54%; p =0.02) or type of calcineurin use at baseline (75% of CsA patients received EPO vs 46% of those on Tac, p < 0.01). An SVR was achieved in 35 of 80 EPO patients (44%) and in 23/58 non-EPO patients (40%) (pNS). Early viral response, end-of-treatment viral response and relapse rates were also similar between groups. The percentage of RBVR dose reductions was greater in the EPO group (76% vs 36%; p< 0.01). The remaining parameters related to tolerability (treatment duration, RBVR discontinuation, IFN dose adherence) did not differ between groups. Conclusions: Ribavirin premature discontinuation was independently associated with SVR in liver transplant patients treated with pegIFN-ribavirin for recurrent hepatitis C. While the use of EPO did not result in a greater viral response, its unavailability might have had resulted in a greater rate of RBVR discontinuation and thereby lower SVR." @default.
- W2063205144 created "2016-06-24" @default.
- W2063205144 creator A5038173955 @default.
- W2063205144 creator A5062157735 @default.
- W2063205144 creator A5072063835 @default.
- W2063205144 creator A5072821422 @default.
- W2063205144 creator A5076357220 @default.
- W2063205144 creator A5085714638 @default.
- W2063205144 date "2010-04-01" @default.
- W2063205144 modified "2023-09-26" @default.
- W2063205144 title "453 PROSPECTIVE RANDOMIZED TRIAL COMPARING PEGIFNALPHA 2A AND PEGIFN ALPHA 2B WITH RIBAVIRIN IN HCV-LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HEPATITIS C" @default.
- W2063205144 doi "https://doi.org/10.1016/s0168-8278(10)60455-2" @default.
- W2063205144 hasPublicationYear "2010" @default.
- W2063205144 type Work @default.
- W2063205144 sameAs 2063205144 @default.
- W2063205144 citedByCount "0" @default.
- W2063205144 crossrefType "journal-article" @default.
- W2063205144 hasAuthorship W2063205144A5038173955 @default.
- W2063205144 hasAuthorship W2063205144A5062157735 @default.
- W2063205144 hasAuthorship W2063205144A5072063835 @default.
- W2063205144 hasAuthorship W2063205144A5072821422 @default.
- W2063205144 hasAuthorship W2063205144A5076357220 @default.
- W2063205144 hasAuthorship W2063205144A5085714638 @default.
- W2063205144 hasConcept C126322002 @default.
- W2063205144 hasConcept C197934379 @default.
- W2063205144 hasConcept C203014093 @default.
- W2063205144 hasConcept C2522874641 @default.
- W2063205144 hasConcept C2776408679 @default.
- W2063205144 hasConcept C2776455275 @default.
- W2063205144 hasConcept C2776461080 @default.
- W2063205144 hasConcept C2778375690 @default.
- W2063205144 hasConcept C2778715236 @default.
- W2063205144 hasConcept C2780040827 @default.
- W2063205144 hasConcept C71924100 @default.
- W2063205144 hasConcept C90924648 @default.
- W2063205144 hasConceptScore W2063205144C126322002 @default.
- W2063205144 hasConceptScore W2063205144C197934379 @default.
- W2063205144 hasConceptScore W2063205144C203014093 @default.
- W2063205144 hasConceptScore W2063205144C2522874641 @default.
- W2063205144 hasConceptScore W2063205144C2776408679 @default.
- W2063205144 hasConceptScore W2063205144C2776455275 @default.
- W2063205144 hasConceptScore W2063205144C2776461080 @default.
- W2063205144 hasConceptScore W2063205144C2778375690 @default.
- W2063205144 hasConceptScore W2063205144C2778715236 @default.
- W2063205144 hasConceptScore W2063205144C2780040827 @default.
- W2063205144 hasConceptScore W2063205144C71924100 @default.
- W2063205144 hasConceptScore W2063205144C90924648 @default.
- W2063205144 hasLocation W20632051441 @default.
- W2063205144 hasOpenAccess W2063205144 @default.
- W2063205144 hasPrimaryLocation W20632051441 @default.
- W2063205144 hasRelatedWork W2014963784 @default.
- W2063205144 hasRelatedWork W2018102323 @default.
- W2063205144 hasRelatedWork W2023575694 @default.
- W2063205144 hasRelatedWork W2033052721 @default.
- W2063205144 hasRelatedWork W2034932599 @default.
- W2063205144 hasRelatedWork W203587163 @default.
- W2063205144 hasRelatedWork W2046096648 @default.
- W2063205144 hasRelatedWork W2058230403 @default.
- W2063205144 hasRelatedWork W2088598737 @default.
- W2063205144 hasRelatedWork W2159259791 @default.
- W2063205144 hasRelatedWork W2195432496 @default.
- W2063205144 hasRelatedWork W2343703333 @default.
- W2063205144 hasRelatedWork W2349679600 @default.
- W2063205144 hasRelatedWork W2396297387 @default.
- W2063205144 hasRelatedWork W2412530943 @default.
- W2063205144 hasRelatedWork W2462759177 @default.
- W2063205144 hasRelatedWork W2471457656 @default.
- W2063205144 hasRelatedWork W2891545121 @default.
- W2063205144 hasRelatedWork W2894630148 @default.
- W2063205144 hasRelatedWork W2977354864 @default.
- W2063205144 isParatext "false" @default.
- W2063205144 isRetracted "false" @default.
- W2063205144 magId "2063205144" @default.
- W2063205144 workType "article" @default.